Kybella Side Effects: Nerve Injury, Dysphagia, and What the Label and FDA Reports Show

Kybella (deoxycholic acid) is the only FDA-approved injectable drug for reducing fat under the chin. The treatment works — but the side-effect discussion is more involved than the marketing suggests. The short answer for most patients: the common effects (swelling, bruising, pain, numbness) are expected, temporary, and part of how the drug destroys fat cells. Two side effects are serious enough that the FDA calls them out by name on the label — jaw-nerve injury that can cause an uneven smile, and trouble swallowing (dysphagia) — and both resolved on their own in the clinical trials. A smaller set of patients deal with numbness and firmness that lingers for weeks after a session, and off-label use outside the chin carries the highest risk of all.

This article lays out what the FDA-approved Kybella label reports from its two pivotal trials, what real-world postmarketing reports add to that picture, and what to ask a licensed clinician before a first session. It is educational, not a diagnosis or a treatment plan. Nothing here should replace individualized advice from a qualified provider.

How Kybella works — and why its side effects make sense

Kybella is a synthetic form of deoxycholic acid, a bile acid the body already uses to break down dietary fat. When injected into the fat pad beneath the chin (the submental area), it destroys the cell membranes of fat cells. The body then clears the debris over the following weeks. The FDA approved Kybella (NDA 206333) in April 2015 for "improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults."

Because deoxycholic acid is a cytolytic drug — it lyses (breaks open) cells by chemistry, not by a targeted mechanism — it does not distinguish fat cells from any other cell it touches. If it strays outside the submental fat pad, it damages whatever tissue it contacts: skin, small blood vessels, or the nerves that control the lower face. That is the root of almost every Kybella side effect worth understanding. The label explicitly warns that the drug "can also destroy other types of cells, such as skin cells, if it is inadvertently injected into the skin," and that injection near vulnerable anatomy raises the risk of tissue damage and vascular injury.

Each treatment session typically involves a grid of small injections, with most patients needing two to six sessions spaced at least a month apart. More sessions and larger treatment areas mean more cumulative exposure — and a wider margin for placement error.

What the clinical trials found: the backbone numbers

The FDA label reports results from two double-blind, placebo-controlled pivotal trials pooling 513 subjects treated with Kybella against 506 given placebo. The population was 19–65 years old, about 85% women, with moderate-to-severe submental fullness. The most common adverse reactions (those occurring in more than 20% of subjects) are the expected injection-site effects.

A few things stand out. Swelling, bruising, pain, and numbness are nearly universal after a real Kybella session — not rare "side effects" but expected consequences of injecting a cell-destroying acid into tissue. Numbness, in particular, hit 66% of Kybella subjects versus only 6% of placebo, which is the fingerprint of the drug acting on small sensory nerves in the area. Bruising (hematoma) was almost as common in placebo (70%) as in Kybella (72%), meaning it is driven mostly by the needle, not the drug.

The two FDA-flagged serious effects, explained

Marginal mandibular nerve injury (the "uneven smile")

The marginal mandibular nerve is the branch of the facial nerve that controls the muscles of the lower lip and chin. If Kybella is injected too close to it — typically too low, toward the jawline, or outside the defined submental treatment zone — the drug can injure the nerve. The result is weakness of the lower face on that side, most visible as an asymmetric (crooked) smile or an inability to pull the lower lip down evenly.

The label reports this happened in 4% of Kybella-treated subjects (20 of 513) versus fewer than 1% on placebo. The reassuring detail: every case in the trials resolved on its own without surgery or additional treatment, with a median recovery time of 44 days (range 1 to 298 days). In other words, most nerve injuries cleared within about six weeks, but some took close to ten months. The prevention is purely anatomical — the provider must keep the injections within the submental fat pad and away from the nerve's path, which is why technique and knowledge of the anatomy matter more than the drug itself.

Dysphagia (trouble swallowing)

Difficulty swallowing occurred in 2% of Kybella subjects (10 of 513), versus fewer than 1% on placebo. The label notes it arose "in the setting of administration site reactions" — that is, the swelling, pain, and firmness under the chin after injection can mechanically interfere with swallowing, rather than the drug directly damaging the swallowing mechanism. Every case resolved spontaneously, with a median of just 3 days (range 1 to 81 days).

Because swelling under the chin is what drives dysphagia, the FDA excluded anyone with a current or prior history of swallowing problems from the trials and warns against using Kybella in those patients, since the treatment can worsen an existing condition. This is one of the clearest examples of a "not a candidate" rule — a patient with baseline dysphagia should not be treated.

What lingers: side effects that last more than a month

Most Kybella side effects clear within a few days to two weeks. But the label tracks effects that lasted more than 30 days and occurred in more than 10% of subjects — the ones patients are most likely to find bothersome:

• Injection-site numbness — 42%
• Injection-site edema/swelling — 20%
• Injection-site pain — 16%
• Injection-site induration (firmness) — 13%

In plain terms, numbness under the chin persisted beyond a month in well over a third of treated subjects, and about one in five still had noticeable swelling at that point. These are not permanent injuries in the trial data, but they are not a "back to normal by Monday" recovery either. Patients scheduling a Kybella session around a wedding or a photoshoot should plan for visible swelling and firmness that can last weeks, not hours.

What real-world reports add

Clinical trials are controlled and fairly small. After approval, the FDA collects real-world reports through its FAERS (FDA Adverse Event Reporting System) database. FAERS is a passive, voluntary system — it cannot be used to calculate how often something happens in the real world, it undercounts heavily, and a report records an event that followed a drug, not proof the drug caused it. Still, it is the closest thing to a postmarket signal for an injectable drug.

An analysis of public FAERS records naming Kybella (52 reports received between February 2016 and March 2025) shows the same two themes the label flagged, plus a few it does not emphasize. The most frequently reported reaction terms included:

• Facial paresis (9 reports) and facial paralysis (3) — the real-world version of the jaw-nerve injury on the label.
• Facial asymmetry (5) — often the visible sign of that nerve weakness.
• Nerve injury (3) and hypoaesthesia (6, reduced sensation) — nerve and sensory effects in the treatment area.
• Injection-site swelling (6), swelling of the face (6), and generalized swelling (4) — consistent with the swelling that drives dysphagia.
• Pain (9) and injection-site pain (8) — expected but occasionally prominent enough to be reported.
• Skin laxity (3) — loosening or sagging of skin, a known concern when fat is removed without tightening the overlying skin.
• "Off label use" (20 reports) — the single most common coding, discussed below.

The small total count (52) reflects Kybella's relatively low treatment volume compared with botulinum toxins or hyaluronic-acid fillers, and FAERS's known underreporting — not that these effects are rare in absolute terms. What the reports do confirm is that the label's two flagged effects show up in the wild, and that sensory and swelling effects dominate the real-world picture much as they do in the trials.

Off-label use is where the risk concentrates

Kybella is approved only for submental fat — the pocket under the chin. It is routinely used off-label elsewhere: the jowls, the "bra fat," the inner thighs, the abdomen, and around the knee. The label's safety data does not cover these areas, and the anatomy (nerves, vessels, skin thickness) is different at each site.

FAERS coding bears this out: "off label use" was the most frequent reaction term in Kybella reports (20 of 52), and several reports also coded "drug ineffective" or "drug ineffective for unapproved indication." When Kybella is injected into areas it was not studied for, the two FDA-flagged risks — nerve injury and damage to surrounding tissue — become harder to control, because the safe injection boundaries mapped for the chin simply do not apply. A patient considering Kybella anywhere other than under the chin should know that the safety numbers above come from submental treatment only, and should ask the provider explicitly about the evidence and the anatomy for the area being treated.

Who is not a candidate, and what to ask

Based on the label and postmarketing data, the clearest non-candidate situations are:

• Current or prior dysphagia — the label contraindicates this; treatment can worsen swallowing trouble.
• Infection at the injection site — the only formal contraindication; the area must be infection-free.
• Significant skin laxity under the chin — removing fat without tightening loose skin can worsen the appearance of sagging (the "skin laxity" reports in FAERS point here). Patients with loose skin may be better served by a tightening procedure or surgery.
• Use of antiplatelet or anticoagulant medication, or a bleeding disorder — the label warns these raise bruising and hematoma risk.
• Treatment outside the submental area — off-label, with anatomy-dependent nerve and tissue risks not covered by the label data.

Postmarketing reports have also included rarer but serious events not emphasized in the trials: injection-site ulceration, necrosis (tissue death), infection, and alopecia (hair loss) at the injection site, as well as hypersensitivity reactions (rash, hives, itching) and scarring. Injections placed too superficially into the dermis are the recognized cause of the ulceration and necrosis cases, and some reported injection-site infections have progressed to cellulitis or abscess requiring antibiotics and, in some cases, incision and drainage. These are uncommon but are the reason any spreading pain, skin color change, open sore, or asymmetric smile after a session warrants prompt contact with the treating provider.

Before a first session, the questions worth asking a licensed clinician are concrete:

1. Are you treating only the submental area, or somewhere off-label? If off-label, what is the evidence and what anatomy are you avoiding?
2. How do you avoid the marginal mandibular nerve? A specific answer about injection depth and placement is a good sign; vagueness is not.
3. What should I expect for swelling, numbness, and firmness, and for how long? Anyone quoting a same-week full recovery is not reading the label data.
4. Given my skin laxity, is Kybella the right tool, or would tightening or surgery fit better?
5. What is the plan if I develop an uneven smile, swallowing trouble, or skin changes after a session?

Kybella's side effects are mostly predictable and time-limited when the drug is used on-label by a provider who understands the anatomy. The label and the postmarketing data together describe a real but manageable risk profile — one that is worth understanding in full before the first injection, rather than after.

Sources

• KYBELLA (deoxycholic acid) injection, Full Prescribing Information — U.S. FDA: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/206333s005lbl.pdf
• KYBELLA Prescribing Information (2020 labeling): https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206333s002s003lbl.pdf
• FDA, Medical Review / Office Director Memo, NDA 206333 (Kybella approval, 2015): https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206333Orig1s000ODMemo.pdf
• Kybella (deoxycholic acid) — Medscape drug reference (warnings, adverse reactions, postmarketing): https://reference.medscape.com/drug/kybella-deoxycholic-acid-999993
• American Med Spa Association, "FDA Approves Treatment for Fat Below the Chin" (Kybella approval and safety summary): https://www.americanmedspa.org/news/fda-approves-treatment-for-fat-below-the-chin
• U.S. FDA, FAERS (FDA Adverse Event Reporting System) public data — analysis of reports naming Kybella, Feb 2016 – Mar 2025 (run June 2026): https://www.fda.gov/drugs/surveillance/questions-and-answers-fdas-adverse-event-reporting-system-faers